Abstract

Etoricoxib belongs to the class of highly selective COX-2 inhibitor NSAIDs. It is mostly used for the treatment of pain, arthritic conditions including rheumatoid arthritis and osteoarthritis. The current study focuses primarily on analytical and bioanalytical method development methodologies, as well as numerous methods established for the estimation of etoricoxib, whether in pharmaceutical dose form or in bulk. Analytical procedures are critical for determining compositions, as they allow us to obtain both qualitative and quantitative results utilising advanced analytical tools. The analytical method for Etoricoxib may be chromatographic, electrochemical, spectral or hyphenated. These methods aid in the comprehension of critical process parameters as well as the minimization of their impact on precision and accuracy. Analytical method development is required to sustain high commercial product quality standards and to meet regulatory requirements. Following the reference, regulatory organisations in several nations have established standards and procedures for providing approval, authentication, and registration. Bioanalytical methods are designed to quantify the concentration of drug, metabolite, or typical biomarkers from various biological fluids including serum, urine, saliva and tissue extracts.

Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.